Phase II Trial of Radiation Dose Escalation With Conformal External Beam Radiotherapy and High-Dose-Rate Brachytherapy Combined With Long-Term Androgen Suppression in Unfavorable Prostate Cancer: Feasibility Report

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 2, 2010, Pages 386-392

  Valero, Jeanette ^a   Cambeiro, Mauricio ^a   Galán, Carlos ^b   Teijeira, Mercedes ^c   Romero, Pilar ^d   Zudaire, Javier ^a   Moreno, Marta ^a   Ciérvide, Raquel ^a   Aristu, José Javier ^a   Martínez Monge, Rafael ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Hospital de La Rioja   (Spain)

^c Hospital Divino Valles   (Spain)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

3D CRT; Androgen suppressive therapy; HDR brachytherapy; High and very high risk; Prostate cancer

Indexed keywords

3D-CRT; ANDROGEN SUPPRESSION; DISEASE PROGRESSION; DOSE ESCALATION; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITIES; GLEASON SCORES; HDR BRACHYTHERAPY; HIGH-DOSE-RATE BRACHYTHERAPY; PHASE II; PRE-TREATMENT; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADIATION DOSE; RADIATION THERAPY ONCOLOGY GROUPS; THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY;

FLUORESCENT SCREENS; ONCOLOGY; THREE DIMENSIONAL; TOXICITY; TUMORS;

RADIOTHERAPY;

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DIARRHEA; DILATATION; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEASIBILITY STUDY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEMATURIA; HOT FLUSH; HUMAN; IMPOTENCE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RECTUM HEMORRHAGE; TENESMUS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URETHRA STRICTURE; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEASIBILITY STUDIES; GASTROINTESTINAL TRACT; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; UROGENITAL SYSTEM;

EID: 73649106201     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.01.059     Document Type: Article

References (45)

1. National Comprehensive Cancer Network. Practice guidelines in oncology v. 2 (2008), NCCN, Fort Washington, PA
2. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
3. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
4. Laverdiere J., Nabid A., De Bedoya L.D., et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171 (2004) 1137-1140
5. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
6. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
7. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
8. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
9. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
10. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
11. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
12. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1124-1129
13. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199
14. Lee W.R., Bae K., Lawton C., et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: Analysis of Radiation Therapy Oncology Group study 0019. Cancer 109 (2007) 1506-1512
15. Hurwitz M.D., Halabi S., Ou S.S., et al. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: An initial report of CALGB 99809. Int J Radiat Oncol Biol Phys 72 (2008) 814-819
16. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61 (2005) 1306-1316
17. Martin T., Roddiger S., Kurek R., et al. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 71 (2004) 35-41
18. Kovacs G., and Galalae R. Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: Is lymph node sampling necessary?. Cancer Radiother 7 (2003) 100-106
19. Martinez A., Gonzalez J., Spencer W., et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169 (2003) 974-979
20. Kalkner K.M., Wahlgren T., Ryberg M., et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up. Acta Oncol 46 (2007) 909-917
21. Astrom L., Pedersen D., Mercke C., et al. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 74 (2005) 157-161
22. Deger S., Boehmer D., Roigas J., et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 47 (2005) 441-448
23. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
24. Lawton C.A., Bae K., Pilepich M., et al. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: Analysis of Radiation Therapy Oncology Group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys 70 (2008) 437-441
25. Ataman F., Zurlo A., Artignan X., et al. Late toxicity following conventional radiotherapy for prostate cancer: Analysis of the EORTC trial 22863. Eur J Cancer 40 (2004) 1674-1681
26. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (2008) 2497-2504
27. Lawton C.A., DeSilvio M., Roach III M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007) 646-655
28. Martinez A.A., Demanes D.J., Galalae R., et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 62 (2005) 1322-1331
29. Levegrun S., Jackson A., Zelefsky M.J., et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 63 (2002) 11-26
30. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
31. Fuks Z., Leibel S.A., Wallner K.E., et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 21 (1991) 537-547
32. Kuban D.A. el Mahdi AM, Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys 24 (1992) 409-414
33. Prestidge B.R., Kaplan I., Cox R.S., et al. The clinical significance of a positive post-irradiation prostatic biopsy without metastases. Int J Radiat Oncol Biol Phys 24 (1992) 403-408
34. Stock R.G., Cahlon O., Cesaretti J.A., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352-1359
35. Martinez-Monge R., Fernandes P.S., Gupta N., et al. Cross-sectional nodal atlas: A tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology 211 (1999) 815-828
36. Hoskin P.J., Bownes P.J., Ostler P., et al. High dose rate afterloading brachytherapy for prostate cancer: Catheter and gland movement between fractions. Radiother Oncol 68 (2003) 285-288
37. Rodriguez R.R., Nag S., Tripuranemi P., et al. HDR Prostate Working Group recommendations for treatment of prostate cancer with external beam radiation therapy and HDR brachytherapy (May 23-25, 1999), Paper presented at the American Brachytherapy Society Meeting, San Diego, CA
38. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
39. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47 (2000) 13-47
40. Late effects consensus conference: RTOG/EORTC. Radiother Oncol 35 (1995) 5-7
41. Hellerstedt B.A., and Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52 (2002) 154-179
42. Horwitz E.M., Winter K., Hanks G.E., et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 947-956
43. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
44. Ludbrook J.J., Greer P.B., Blood P., et al. Correction of systematic setup errors in prostate radiation therapy: How many images to perform?. Med Dosim 30 (2005) 76-84
45. Kim Y., Hsu I.C., Lessard E., et al. Dosimetric impact of prostate volume change between CT-based HDR brachytherapy fractions. Int J Radiat Oncol Biol Phys 59 (2004) 1208-1216